Ok so I want to start off with a few things before I get

New Post Public Reply Private Reply Replies (18) Message Board
1990
5,596
Ok so I want to start off with a few things before I get into the interview. I would like to start off by commending Ziv. He was willing to meet with me at 8am (even though they start work significantly later to mirror American hours) and he allotted essentially an infinite amount of time for me. I want to follow up with an apology to you guys.  I had to catch a flight and this was very last minute so I only had about half an hour with him. I didn't get to get as deep into it as I would like or get to ask all the questions submitted. That being said I will detail the brief interview below. There will be some places where I insert my opinion and I will make those points clear.

First and foremost the office definitely exists guys haha. It's a standard office with a beautiful lobby in a mini office park. The outside looks average but inside it looks  modern.  I took a few pictures and am on my phone now. Maybe I can post them from my computer later? I also passed by tel hashomer hospital. I have asked many people there about it and it's reputation is outstanding.

Now on to the interview

Q: what other uses are being tested for the cream? I believe I heard something about basal cell carcinoma

A: I can't get into those details but I can tell you basal cell carcinoma is not something we are testing now. It is definitely on our radar for the near future

Q: does the cream have any side effects? What makes it different from other products?

A: no there are no side effects which is a benefit of this cream unlike other medications. Also our product is natural and does not have chemicals in it like other treatments. Furthermore I believe our product will be the only psoriasis cream clinically tested on the market. If you can find another cream that was let me know (this is Ziv btw)

Q: what country do you plan to market to first?

A: US but we are also excited to take advantage of the European market. It's huge and often gets overlooked.

Q: so you want to enter the US market. This is through Medmar correct? Is this the same one in Illinois?

A: yes we will distribute through Medmar. No it's not the same company in Illinois.

Q: consulting contracts. When do you expect to generate revenue from them

A: sometime this year

Q: any myeloma updates?

A: not that I can say

Q: well are you more advanced then the previous article about killing 100% in 60% of myeloma cells in tested animals?

A: yes we are more advanced than that. I can't comment on specifics unfortunately. I don't want to tip off competition. 

Q: how many patents do you have. Are they all provisional? Are they all protected by USPTO?

A: 8 provisional and they are all protected by USPTO. We filled the provisional with the intention of working our way to a real patent. It's a process. We also filled a PCT patent on five of them which extends our ownership of idea and time period for 18 months as we flush out these concepts further.  But yes these are currently  protected. 

Q: is the condom one of those

A: of course it could be a fun way to take/give medication

Q: what other diseases are currently in the pipeline?

A: I cannot mention anything that wasn't published but there are others

Q: who do you see as your biggest competitor?

A: no competition at the moment. There are so many possibilities for cannabis and medical application that there isn't any reason for people to step on each other's toes. The more people who embrace cannabis the more beneficial it is for the industry.

Q: will you touch the raw plant or just oils

A: just oils for now

Q: are the rumors about Teva trying to buy you out true?

A:  they called us and wanted to sign an NDA to have access to our information. There was no reason for us to give them access to our intellectual property/information so we denied their request.

Q: why did you go public?

A: three years ago cannabis was not taken seriously. When I told my mother what I was doing she thought I was a drug dealer and wanted nothing to do with it. Others had a similar reaction   At the time buying the ticker was the only way to raise funds. If I could have raised the money at the time I would have preferred to be private. (MY OPINION: now cannabis is more widely accepted I think their recent partnerships and agreements point to this. Their non dilutive financing points to their current goals not to just keep issuing shares. I also think this rarity is why we have found such a gem and ground floor opportunity. Had cannabis been widelt accepted in 2014 I don't think theyd be public right now )

Me: well I'm glad you went public haha

He then let me see the cream. While I don't have psoriasis I can say the cream didn't have any noticable negative effects on my skin. Cream is kind of thick and you can smell the weed haha but the smell subsidies after rubbing it on.

MY OPINION: while he didn't say it, from my own interpretations of body language and context clues, I believe efficacy is a given. It almost seemed as if it was assumed that it was coming to market throughout our convo  Once again this is my opinion not fact.

Also MY OPINION from talking to him he is aware of the fluctuations in the stock price but doesn't seem concerned. I get the impression he believes long term everything will work itself out.

Overall he was very nice and willing to answer all my questions. I know there are quite a few topics that might have benefitted from a deeper dive but do to my own time restrictions I couldn't get to those. I hope at least one of these answers helps y'all in your DD  

OWC Pharmaceutical Research Corp. (OWCP) Stock Research Links

OWCP Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 5

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 12

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading

Top 5 Most Recently Viewed Articles

Strengthening User Protection in Cryptocurrency Trading

Updated Category News Views 189

Goldenes Intelligentes Münzhandelszentrum Enhances Trading Security Goldenes Intelligentes Münzhandelszentrum has unveiled a significant upgrade to its global user protection framework, positioning itself and its users ahead in the competitive landscape of crypto derivatives exchange. Enhanced Security Features This upgrade addresses increasing cybersecurity threats and...

Continue Reading
Upcoming Earnings: What to Expect from PPG Industries

Updated Category News Views 100

Anticipating the PPG Industries Earnings Report PPG Industries (PPG) is gearing up for its next quarterly earnings announcement, creating buzz among investors eager for insights into its financial performance. The anticipated date for this announcement is fast approaching, sparking interest and speculation. Analysts have set expectations, projecting that PPG Industries...

Continue Reading
Join the Class Action for Reckitt Benckiser Shareholders Now

Updated Category News Views 149

Understanding the Class Action for Reckitt Benckiser Shareholders Attention shareholders of Reckitt Benckiser Group plc (RBGLY). If you purchased shares during the specified class period, there is an important opportunity to join a class action. This notice is particularly pertinent for those who may have suffered losses due to the company's alleged misleading statements...

Continue Reading
Craig Gentry Strengthens Cornami's Encryption Innovations

Updated Category News Views 122

Craig Gentry Joins Cornami, Boosting Cryptographic Expertise Cornami, a company dedicated to innovative computing solutions, has appointed Dr. Craig Gentry as their Chief Scientist for Algorithms. With Dr. Gentry's impressive background in cryptography, Cornami aims to enhance its vision of providing real-time encrypted computing capabilities. About Dr. Craig Gentry: A...

Continue Reading
ICG Enterprise Trust Executes Strategic Share Buyback Initiative

Updated Category News Views 172

ICG Enterprise Trust Ongoing Commitment to Shareholder Value ICG Enterprise Trust plc has recently taken a notable step in its commitment to maximizing shareholder value. On November 19, 2024, the company initiated a buyback of 10,000 of its own shares, a strategic move aimed at optimizing its share structure. Details of the Share Buyback The shares were repurchased at an...

Continue Reading